Merrimack Pharmaceuticals Initiates Phase 1 Clinical Study of MM-141 in Patients With Advanced Solid Tumors

[at noodls] – CAMBRIDGE, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 clinical study of a novel compound for the … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view